A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
← catalyst calendarNCT07483073 · readout ≤ 315 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
60estimated
Sites
70
Countries
Belgium, Brazil, Canada +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-04 | actual | When the study began enrolling |
| Primary completion | Jun 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Colitis, Ulcerative
- Crohn Disease
Interventions
- Drug: Mirikizumab - Intravenous (IV) — also filed as LY3074828
- Drug: Mirikizumab - Subcutaneous (SC) — also filed as LY3074828
- Drug: LY4395089
Primary outcome
what the primary-completion date above is the date OFNumber of Participants Allocated to Each of the Intervention-Specific Appendices (ISA)
measured Baseline, Up to Day 42
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed